TICKERNOMICS Sign up
Last Update: 2024-12-27 15:29:15
bioAffinity Technologies Inc. ( BIAF ) https://www.bioaffinitytech.com
0.95USD
Sector:
Healthcare
Industry:
Diagnostics & Research
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-43.11%
BIAF
SPY
32.66%
BIAF
0.00%
SPY
108.59%
BIAF
0.00%
SPY
302.52%
BIAF
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
11.77
11.04
0.12
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.39
1.26
3.77
-31.29
0.00
-1.50
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-83.98
100.00
-77.62
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.32
-85.74
-93.80
0.00
Other Earnings and Cash Flow Stats:
bioAffinity Technologies Inc. ( BIAF ) Net Income TTM ($MM) is -8.45
bioAffinity Technologies Inc. ( BIAF ) Operating Income TTM ($MM) is -8.35
bioAffinity Technologies Inc. ( BIAF ) Owners' Earnings Annual ($MM) is 0.00
bioAffinity Technologies Inc. ( BIAF ) Current Price to Owners' Earnings ratio is 0.00
bioAffinity Technologies Inc. ( BIAF ) EBITDA TTM ($MM) is -7.75
bioAffinity Technologies Inc. ( BIAF ) EBITDA Margin is -77.62%
Capital Allocation:
bioAffinity Technologies Inc. ( BIAF ) has paid 0.00 dividends per share and bought back -3.695313 million shares in the past 12 months
bioAffinity Technologies Inc. ( BIAF ) has reduced its debt by 0.376581 million USD in the last 12 months
Capital Structure:
bioAffinity Technologies Inc. ( BIAF ) Interest-bearing Debt ($MM) as of last quarter is 0
bioAffinity Technologies Inc. ( BIAF ) Annual Working Capital Investments ($MM) are -1
bioAffinity Technologies Inc. ( BIAF ) Book Value ($MM) as of last quarter is 3
bioAffinity Technologies Inc. ( BIAF ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
bioAffinity Technologies Inc. ( BIAF ) has 0 million in cash on hand as of last quarter
bioAffinity Technologies Inc. ( BIAF ) has 2 million of liabilities due within 12 months, and long term debt 0 as of last quarter
bioAffinity Technologies Inc. ( BIAF ) has 12 common shares outstanding as of last quarter
bioAffinity Technologies Inc. ( BIAF ) has 0 million USD of preferred stock value
Academic Scores:
bioAffinity Technologies Inc. ( BIAF ) Altman Z-Score is -11.33 as of last quarter
bioAffinity Technologies Inc. ( BIAF ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
bioAffinity Technologies Inc. ( BIAF ) largest shareholder is CapTrust Financial Advisors owning 43642 shares at 0.04 ($MM) value
(an insider) shares of bioAffinity Technologies Inc. ( BIAF ) for the amount of $ on
29.55% of bioAffinity Technologies Inc. ( BIAF ) is held by insiders, and 2.47% is held by institutions
bioAffinity Technologies Inc. ( BIAF ) went public on 2022-09-01
Other bioAffinity Technologies Inc. ( BIAF ) financial metrics:
FCF:-7.27
Unlevered Free Cash Flow:0.00
EPS:-0.65
Operating Margin:-83.98
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-256.43
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About bioAffinity Technologies Inc. ( BIAF ) :
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.